Dermatomyositis as a complication of interferon-α therapy: A case report and review of the literature

Rheumatology International

Volumn 34, Issue 9, 2014, Pages 1319-1322

  Shiba, Hideyuki ^a   Takeuchi, Tohru ^a   Isoda, Kentaro ^a   Kokunai, Yasuhito ^a   Wada, Yumiko ^a   Makino, Shigeki ^a   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Dermatomyositis; Hepatitis C; Interferon ; Polymyositis; Tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO ACID TRANSFER RNA LIGASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CD4 ANTIGEN; CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; IMMUNOGLOBULIN; MUSCLE ENZYME; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISOLONE; RIBAVIRIN; TACROLIMUS; ALPHA INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BLOOD EXAMINATION; CASE REPORT; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; DERMATOMYOSITIS; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; GRIP STRENGTH; HEPATITIS C; HUMAN; JAPANESE (PEOPLE); MALAISE; MALE; MIDDLE AGED; MONOCYTE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SKIN BIOPSY; WEIGHT REDUCTION; BIOPSY; CHEMICALLY INDUCED; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BIOPSY; DERMATOMYOSITIS; HEPATITIS C; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84906937828     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-2984-4     Document Type: Article

References (23)

1. Kao L, Chung L, Fiorentino DF (2011) Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep 13:225-232
2. Saida T, Tashiro K, Itoyama Y et al (2005) Interferon Beta-1b multiple sclerosis study group of Japan. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 64:621-630 (Pubitemid 40261889)
3. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344-347
4. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403-407
5. Aouba A, Georgin-Lavialle S, Terrier B et al (2011) Anti-PL7 antisynthetase syndrome under interferon therapy. Joint Bone Spine 78:94-97
6. Dietrich LL, Bridges AJ, Albertini MR (2000) Dermatomyositis after interferon alpha treatment. Med Oncol 17:64-69 (Pubitemid 30159170)
7. John A, El Emadi S, Al Kaabi S et al (2007) Polymyositis during pegylated alpha-interferon ribavirin therapy for chronic hepatitis. Indian J Gastroenterol 26:147-148 (Pubitemid 47296217)
8. Matsuya M, Abe T, Tosaka M et al (1994) The first case of polymyositis associated with interferon therapy. Intern Med 33:806-808
9. Ferri C, La Civita L, Fazzi P et al (1996) Polymyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection. Arthritis Rheum 39:1074-1075
10. Venezia G, Licata A, Di Marco V et al (2005) Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. Dig Liver Dis 37:882-885 (Pubitemid 44356118)
11. Lee SW, Kim KC, Oh DH et al (2002) A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B. J Korean Med Sci 17:141-143
12. Hengstman GJ, Vogels OJ, ter Laak HJ et al (2000) Myositis during long-term interferon-alpha treatment. Neurology 54:2186
13. Cirigliano G, Della Rossa A, Tavoni A et al (1999) Polymyositis occurring during alpha-interferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int 19:65-67 (Pubitemid 30025691)
14. Falcone A, Bodenizza CA, Musto P et al (1998) Symptomatic myopathy during interferon alpha therapy for chronic myelogenous leukemia. Leukemia 12:1329 (Pubitemid 28396002)
15. Bonaci-Nikolic B, Jeremic I, Andrejevic S et al (2009) Antidouble stranded DNA and lupus syndrome induced by interferonbeta therapy in a patient with multiple sclerosis. Lupus 18:78-80
16. Sladkova V, Mares J, Lubenova B et al (2011) Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. Neuro Endocrinol Lett 32:4-6
17. Warabi Y, Matsubara S, Mizutani T et al (2004) Inclusion body myositis after interferon-alpha treatment in a patient with HCV and HTLV-1 infection. Rinsho Shinkeigaku 44:609-614 [in Japanese] (Pubitemid 39318741)
18. Watt K, Veldt B, Charlton M (2009) A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 9:1707-1713
19. Kyogoku C, Tsuchiya N (2007) A compass that points to lupus: genetic studies on type I interferon pathway. Genes Immun 8:445-455 (Pubitemid 47365611)
20. Wenzel J, Schmidt R, Proelss J (2006) Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 31:576-582 (Pubitemid 43806596)
21. Greenberg SA (2007) Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 69:2008-2019
22. Greenberg SA, Pinkus JL, Pinkus GS et al (2005) Interferon-alpha/beta- mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57:664-678 (Pubitemid 40628855)
23. Baechler EC, Bauer JW, Slattery CA et al (2007) An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13:59-68 (Pubitemid 46786834)